ESMO: Lilly's Verzenio looks for an edge with gold-standard data in tough-to-treat patients

29th September 2019 Uncategorised 0

It’s tough to be a third-to-market drug, particularly when you’re trailing a first-up launch like Pfizer’s blockbuster Ibrance. But with some new data showing Verzenio can help tough-to-treat breast cancer patients live significantly longer, Eli Lilly’s hoping for a kick-start for its contender.

More: ESMO: Lilly's Verzenio looks for an edge with gold-standard data in tough-to-treat patients
Source: fierce